Synopsis: Vijay Kedia’s firm sold Mangalam Drugs via bulk deals, selling 1.38 lakh shares. Other participants included Neo Apex, Epitome Trading, and Multiplier Advisors. The total bulk deal value reached Rs. 1.62 crore, while the stock hit 5% upper circuit.
This company manufactures bulk drugs, organic and inorganic chemicals is among the few companies that are World Health Organisation-approved companies is now in focus after Vijay Kedia’s firm sold a stake in it.
With a market capitalisation of Rs. 58 cr, the shares of Mangalam Drugs & Organics Ltd are currently trading at Rs. 36.93 per share, hitting an upper circuit of 5% in today’s market session, up from its previous close of Rs. 35.18 per share. In the last month, the stock delivered a 49% return.
Bulk deal
Mangalam Drugs & Organics witnessed significant activity in the bulk deals segment on Wednesday. Notably, Vijay Kedia’s Kedia Securities sold approximately 1.38 lakh shares worth Rs. 48.35 lakh, highlighting a major sale by a prominent investor.
Other participants in the bulk deals included Neo Apex Venture LLP (Rs. 27.6 lakh), Epitome Trading and Investments (Rs. 42 lakh), and Multiplier Share & Stock Advisors Pvt Ltd (Rs. 44 lakh), indicating multiple institutional-level trades on the stock. The total value of these deals is around Rs. 1.62 cr.
About the company
Mangalam Drugs & Organics Ltd manufactures Active Pharmaceutical Ingredients (APIs) and intermediates. With multi-location facilities and an in-house R&D recognised by DSIR, the company is a leading global supplier of Anti-Malaria APIs and has a diversified product portfolio. It ranks among the top in Asia for its products and is the largest producer of some globally.
The company shows moderate capital efficiency with an ROCE of 8.03%, but low returns to shareholders of ROE 4.71. Its debt-to-equity ratio of 0.74 indicates a reasonable level of leverage, while a low price-to-book value of 0.46 suggests the market sees it as undervalued.
Sales of the company fell from Rs. 57.35 cr in Q1FY26 to Rs. 49.54 cr in Q2FY26. Operating loss at Rs. 2.83 from Rs. 4.51 cr. Net loss narrowed from Rs. 13.73 cr to Rs. 7.25 cr.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Bulk Deal: Stock hits 5% upper circuit after Vijay Kedia sold stake in the company appeared first on Trade Brains.